Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid abnormalities. In this Perspectives in Diabetes article, we emphasize that changing demographics and lifestyles over the past few decades have resulted in an epidemic of the “atherogenic dyslipidemia complex,” the main features of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL particles, accumulation of remnant lipoproteins, and postprandial hyperlipidemia. We briefly review the underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin resistance, obesity, and type 2 diabetes, and the marked atherogenicity of this condition. We explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors that are known to modify components of the atherogenic dyslipidemia complex. Finally, we discuss targeted repurposing of existing therapies and review promising new therapeutic strategies to modify the atherogenic dyslipidemia complex. We postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance with increased circulating FAs and decreased insulin signalling can also lead to increased chylomicron secretion.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
In the citing paper
“This milieu drives increased VLDL secretion, which is particularly enhanced when FA and insulin are in excess.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cited by
Items 101–200 of 211
Bazarbashi, N., & Miller, M. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1749596 · Cited by 11
Predicción de diabetes mellitus basada en el índice triglicéridos y glucosa
Muñiz, C. C., León-García, P. E., Serrato‐Díaz, A., & Hernández‐Pérez, E. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.07.003 · Cited by 16
Jia, Y.-P., Wang, J.-M., Lyu, J.-Q., Yang, H.-H., Miao, M.-Y., Wang, X., Wan, Z.-X., Zheng, Y., Qin, L.-Q., Li, F.-R., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100653 · Cited by 10
Peng, J., Li, D., Liu, L., Xiang, Y., & Tang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1096045 · Cited by 11
“However, research on the underlying mechanism is rarely reported, which may be the direction of our future research (24).”
BackgroundIbi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R. W., Rensen, P. C. N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.015 · Cited by 10
“In addition to LDL-C, TG-rich lipoproteins (TRLs) have recently been identified as an independent additional risk factor for CVD [6 – 8].”
Abedi, A. H., Şimşir, İ. Y., Bayram, F., Önay, H., Özgür, S., McIntyre, A. D., Toth, P. P., & Hegele, R. A. (2023) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2022.98544 · Cited by 12
Song, S., Lee, C. J., Oh, J., Park, S., Kang, S., & Lee, S. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.58 · Cited by 9
Ghodsi, S., Mohebi, M., Sadre‐Bafghi, S., Poorhosseini, H., Salarifar, M., Alidoosti, M., Hajizeinali, A., Amirzadegan, A., Aghajani, H., Jenab, Y., et al. (2021) · Clinical Cardiology · doi:10.1002/clc.23610 · Cited by 9
“However, frequency of atherogenic particles including small dense LDL-C increases that tend to get oxidized.(32)”
BackgroundIbi, D., Boot, M., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100193 · Cited by 9
“S2): (1) reference group (higher TG through APOA5 and LPL), (2) lower TG through LPL only, (3) lower TG through APOA5 only, and (4) lower TG through both APOA5 and LPL.”
BackgroundSun, J., Wang, Z., Chen, L., Xia, H., Yang, L., Wang, S., & Sun, G. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.952588 · Cited by 9
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.05.004 · Cited by 9
Wang, S., Tu, J., & Pan, Y. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s232343 · Cited by 9
Pasdar, Y., Moradi, F., Cheshmeh, S., Sedighi, M., Saber, A., Moradi, S., Bonyani, M., & Najafi, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-46447-8 · Cited by 11
“Dyslipidemia is an important predisposing factor in increasing the risk of cardiovascular diseases (CVDs) 1,2 .”
BackgroundAssociation Between Adequate Serum 25(OH)D Levels and Atherogenic Dyslipidemia in Young Adults
Chen, C., Han, Y., Hwang, J.-S., Rizzo, M., Yamashita, S., Hsu, S. H.-J., & Su, T. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64523 · Cited by 12
“While interventions targeting dyslipidemia can alleviate these risks, other types of atherogenic dyslipidemia 4) , notably small-dense low-density lipoprotein cholesterol (sdLDL-C) and low-density lipoprotein triglyceride (LDL-TG), introduce residual threats.”
BackgroundAtherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension
Kazibwe, R., Jehopio, J., Schaich, C. L., Rikhi, R. R., Mirzai, S., Chevli, P. A., Namutebi, J. H., Chebrolu, S., O'Connor, S., Yeboah, J., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.006 · Cited by 12
Yang, F., Min, L., Chen, L., Yang, C., & Liu, A. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2021-1089 · Cited by 8
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8
A New Treatment Strategy for Diabetic Dyslipidemia?
Kothari, V. M., & Bornfeldt, K. (2020) · Diabetes · doi:10.2337/dbi20-0035 · Cited by 8
“The elevated TRLs in T2D are generally attributed to hepatic overproduction of apolipoprotein B (APOB)-containing VLDL, increased intestinal secretion of APOB48 (a truncated form of APOB100 in chylomicrons and their remnants), and dysregulated clearance of TRLs (1,2,6,7), as shown by Fig.”
BackgroundInfluentialCardiovascular autonomic and peripheral sensory neuropathy in women with obesity
Keller, N., Zádori, J., Lippai, B., Szöllősi, D., Márton, V., Wellinger, K., Lada, S., Szűcs, M., Menyhárt, A., Kempler, P., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386147 · Cited by 13
“Further research should be conducted to provide more speci fi c and detailed information on this topic.”
BackgroundCurrent Understanding of Diabetic Dyslipidemia: A Review
Gupta, A., & Gupta, R. (2022) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00346-5 · Cited by 7
Loss of Anthropometry-Lipids Relationship in Obese Adults: A Cross-Sectional Study in Southern China
Huang, W., Feng, R., Xu, X. P., Ma, M., Chen, J., Wang, J., Hu, Z., Du, S., & Ye, W. (2023) · Clinical Epidemiology · doi:10.2147/clep.s400150 · Cited by 8
Dietary Guidance for Cardiovascular Health: Consensus and Controversies
Pietri, P. G. (2023) · Nutrients · doi:10.3390/nu15194295 · Cited by 10
“Atherogenic hyperlipidemia (defined as increased levels of triglycerides, low levels of HDL cholesterol and normal levels of LDL cholesterol, which is composed of small, dense particles), prevalent in obese and overweight patients with abnormal glucose metabolism, is also associated with increased CV risk and may expl…”
BackgroundWang, X., Yu, D., Wang, J., Huang, J., & Li, W. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/2370496 · Cited by 7
“confirmed [24] that the increase of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) and the decrease of high-density lipoprotein (HDL-C) are one of the most important independent risk factors for coronary heart disease.”
BackgroundRetractedJensen, A. H., Ytting, H., Werge, M. P., Rashu, E. B., Hetland, L. E., Thing, M., Nabilou, P., Burisch, J. M., Bojsen-Møller, K. N., Junker, A. E., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00047.2024 · Cited by 11
Control of intestinal lipoprotein secretion by dietary carbohydrates
Stahel, P., Xiao, C., & Lewis, G. F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000474 · Cited by 8
Self-citationLiu, X., Wang, Y., Wu, J., Wang, A., Zhang, X., Cao, Z., & Zhao, X. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.696695 · Cited by 6
Association between the plasma ceramide and coronary microvascular resistance
Feng, L., Zhao, X., Song, J., Yang, S., Xiang, J., Zhang, M., Tu, C., & Song, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02495-6 · Cited by 6
Lan, N. S. R., Fegan, P. G., Yeap, B. B., Rankin, J. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13689 · Cited by 6
Diabetic dyslipidemia and microvascular complications of diabetes
Karásek, D., & Vaverková, H. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.003 · Cited by 6
Wu, L., Zhou, N., Sun, J.-Y., Yu, H., & Wang, R. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001270 · Cited by 6
Leatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 7
Shahraz, J., Joukar, F., Sheida, F., Yeganeh, S., Maroufizadeh, S., Baghaee, M., Naghipour, M., & Mansour‐Ghanaei, F. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70055 · Cited by 8
“C), small dense low‐density lipoprotein (sdLDL), low‐density lipoprotein (LDL) levels, but decreasing in HDL and Apo A1 [14, 15].”
Ren, J., Wang, G., Wang, Y., Li, L., Sun, J., Liu, S., Wu, X., Zhang, C., & Ruan, L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02706-3 · Cited by 5
Pacientes geriátricos con diabetes mellitus tipo 2 e impacto de factores modificables. Perú
Romaní, K. J. O., Quiroz, K. C. M., Rosas, J. G. V., & Montalvo, Y. J. O. (2021) · Gerokomos · doi:10.4321/s1134-928x2021000400005 · Cited by 5
Chen, T., Wang, Z., Xie, J., Xiao, S., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.04.012 · Cited by 5
Silva, A. M. E., Aguíar, C., Duarte, J. S., Couto, L., Veríssimo, M. T., & da Silva, P. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.005 · Cited by 8
The role of chitosan-based nanoparticles to reduce obesity: a glimpse
Rakshit, S., Pal, K., Mondal, K. C., & Halder, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90750-7.00009-0 · Cited by 7
Lee, E. J., Choi, H., Yoon, W. C., Kim, Y., Song, B.-N., Lee, M.-Y., Park, B.-R., Lee, S. H., Choi, J. H., & Park, S.-Y. (2021) · Korean Journal of Medicinal Crop Science · doi:10.7783/kjmcs.2021.29.4.263 · Cited by 5
de la Cruz, S., Leon‐Acuña, A., Yubero‐Serrano, E. M., Torres-Peña, J. D., Larriva, A. P. A.-D., Cardelo, M. P., Rangel-Zúñiga, O. A., Luque, R. M., Alcala-Diaz, J. F., Ordovás, J. M., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.002 · Cited by 5
“…umbrella of dyslipidemia exists a dramatic heterogeneity and complexity, such as the numerous, and potentially significant lipoprotein subfractions pre-sent in the fasting and postprandial states [9,10], but we lack full understanding of their contributions and informativeness as CHD risk factors.”
Hongqu Rice Wines Ameliorate High-Fat/High-Fructose Diet-Induced Metabolic Syndrome in Rats
Zhang, N., Kong, F., Jing, X., Zhou, J., Zhao, L., Soliman, M. M., Zhang, L., & Zhou, F. L. (2022) · Alcohol and Alcoholism · doi:10.1093/alcalc/agac033 · Cited by 4
Profile of Lipoprotein Subclasses in Chinese Primary Open-Angle Glaucoma Patients
Fu, C., Xu, J., Chen, S.-L., Chen, C., Liang, J., Liu, Z., Huang, C., Wu, Z., Ng, T. K., Zhang, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084544 · Cited by 5
“These lipoproteins have been considered as key regulators in atherosclerotic cardiovascular disease and other vascular-related diseases [37,38]. sdLDL, encompassing LDL3 to LDL7, refers to the smaller and denser subclasses of LDL.”
BackgroundFan, W., Philip, S., Toth, P. P., Granowitz, C. B., & Wong, N. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100087 · Cited by 4
“The inclusion criteria for our analysis were [1]: adults aged 40–74 years old (required age range for 10-year ASCVD risk calculation) [2]; with available TG data [3]; with available information to calculate pooled cohort 10-year ASCVD risk; and [4] without prior ASCVD defined as self-reported heart attack, stroke, cor…”
BackgroundMethodThe Significance of Lipoproteins in the Development of Obesity
Blagov, A. V., Rufanov, K. A., Irina, K., Sukhorukov, V. N., Goncharov, A., Pleshko, E. M., & Orekhov, A. N. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601008 · Cited by 4
“These anomalies result from a confluence of factors, including insulin resistance, increased liver absorption of free fatty acids due to visceral and total adiposity, and an inflammatory state brought on by macrophages entering adipose tissue [25].”
BackgroundHistopatologi Hepar Tikus Dengan Induksi Pakan Tinggi Lemak Setelah Pemberian Biji Mahoni
Sijabat, A. C. G., Isdadiyanto, S., & Sitasiwi, A. J. (2024) · Jurnal Ilmu Pertanian Indonesia · doi:10.18343/jipi.29.3.482 · Cited by 3
Yang, R., Chen, S.-L., Ng, T. K., Liang, J., Huang, S., Deng, M., Wu, Z., Sun, Y., Fu, C., Pang, C. P., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02043-7 · Cited by 5
“Hyperlipidemia is caused by abnormal lipid metabolism and is characterized by an increase in total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) cholesterol in the blood, and/or a decrease in high-density lipoprotein cholesterol (HDL-C) [65].”
Wang, G., Sun, X., Chen, X., Zhang, L., Fan, S., Mu, Y., Zheng, D., Huang, X., Xu, J., & Li, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117136 · Cited by 3
Alireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.04 · Cited by 3
Adeli, K., Xiao, C., Higgins, V., Taher, J., Farr, S., & Lewis, G. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824048-9.00002-x · Cited by 3
Self-citationGao, Y., Lei, T., Dang, P., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1512662 · Cited by 2
Duran, E. K., Cook, N. R., Aday, A. W., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.123.039381 · Cited by 4
“–30 Emerging data continue to indicate that TRL-C 31,32 (ie, remnant cholesterol) and small, dense LDL-C 33,34 are strong independent predictors of CVD, and we previously showed risk also associates independent of hsCRP and LDL-C.”
Borkar, A. S., Todorova, Y., & Markey, O. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100694 · Cited by 2
Diabetes mellitus prediction based on the triglyceride and glucose index
Muñiz, C. C., León-García, P. E., Serrato‐Díaz, A., & Hernández‐Pérez, E. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.03.001 · Cited by 2
Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes
Fan, W., & Wong, N. D. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_32 · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
Silva, A. M. E., Aguíar, C., Duarte, J. S., Couto, L., Veríssimo, M. T., & da Silva, P. M. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.03.010 · Cited by 4
“Several studies have shown that the imbalance between elevated TG (which are proatherogenic, especially in the form of cholesterol-rich remnants) and reduced HDL-C increases CV risk independently of LDL-C levels.(6,7) Detection and treatment of atherogenic dyslipidemia thus has an important role in the control of resi…”
BackgroundPatel, O., Muller, C. J. F., Joubert, E., Rosenkranz, B., Louw, J., & Awortwe, C. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.963489 · Cited by 3
Mokhtari, I., Harnaf, M., Amrani, S., Milenković, D., & Harnaf, H. (2023) · Physiology and Pharmacology · doi:10.61186/phypha.27.2.116 · Cited by 2
Liu, Y., Wang, X., Han, J., Liu, L., Jin, Y., Jin, L., & Ye, P. (2019) · Medicine · doi:10.1097/md.0000000000015062 · Cited by 2
Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy
Park, J., & Ovbiagele, B. I. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.49304 · Cited by 2
Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?
Samanta, B. (2019) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0039-1697239 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Khan, S., Lohani, A., Tiwari, P. K., & Kadiri, S. K. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100583 · Cited by 1
Feng, J., Zhang, J., Wang, S., Li, Z., Yuan, H., Yao, H., Xue, J., Zheng, J., Wu, Y., Wang, S., et al. (2025) · npj Science of Food · doi:10.1038/s41538-025-00546-0 · Cited by 2
“…a lipid-driven chronicin fl ammatorydiseaseintheintimaofarteries,ASsharessimilarities with hyperlipidemia, such as decreasedhigh-densitylipoprotein cholesterol (HDL-C) levels, as well as increased total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels 3 .”
Duan, Q., Wang, Y., Xu, J., Cheng, L., Hong, W., Feng, P., Lu, W., Xu, X., & Zhang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1686162 · Cited by 1
“Traditional dyslipidemia, characterized by elevated triglycerides, increased LDL-C, and reduced HDL-C, has long been implicated in the pathogenesis of NAFLD (17, 18).”
Wu, D., Lan, Y., Ding, X., Balmer, L. A., Li, X., Wang, W., Wu, S., & Chen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07028-7 · Cited by 3
“Diabetes and chronic inflammation have been proposed to account for residual cardiovascular risks despite aggressive LDL-C lowering [3–6].”
The unseen impact of subclinical hypothyroidism on lipid profile and cardiovascular risk
Mawlood, M. S. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102605 · Cited by 2
“…indicator of lipid abnormalities and cardiovascular risk in patients with SCH. Elevated TSH concentrations have been associated with unfavorable lipid profiles despite normal levels of circulating thyroid hormones, indicating that TSH may reflect underlying metabolic changes related to SCH [23].”
Management of asymptomatic severe hypertriglyceridemia
Scherer, N. V., & Bista, D. (2021) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2021.1960123 · Cited by 1
“There are also nongenetic determinants that can exacerbate hypertriglyceridemia, including obesity, metabolic syndrome, poorly controlled diabetes mellitus, pregnancy, and certain medications.(2) Severe hypertriglyceridemia is commonly associated with acute pancreatitis but can rarely cause multiorgan system dysfuncti…”
BackgroundMorbidities Related to Obesity- A Short Review of Literature
Butola, L. K., Kanyal, D., & Dhok, A. (2021) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2021/753 · Cited by 1
HUBUNGAN ANTARA PARAMETER ANTROPOMETRI DAN PROFIL LIPID PADA WANITA SEHAT DI SEMARANG
Purwanti, R., & Syauqy, A. (2022) · Gizi Indonesia · doi:10.36457/gizindo.v45i2.666 · Cited by 1
Alshuweishi, Y., Alfayez, D. I., Almufarrih, A. A., Abudawood, A., Alyami, H. M., Alshuweishi, F. A., Al‐Sheikh, Y. A., & Alfhili, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185650 · Cited by 3
Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
Patwekar, M., Patwekar, F., Kumar, J. P., Prasad, P. D., Malik, N., Badarinath, A. V., Parupathi, P. R., Reddy, K. T. K., Elumalai, S., & Samad, Z. A. A. (2025) · BIO Integration · doi:10.15212/bioi-2024-0047 · Cited by 3
“Future clinical uses of DGAT1 inhibitors as innovative therapeutic options for diabetes and related metabolic disorders offer promise for further study and development [60, 61].”
Pan, P., Li, Q. X., Lin, H., Dong, L., Lv, K., & Wang, Z. (2025) · Medicine · doi:10.1097/md.0000000000044087 · Cited by 3
“[1] The source of human blood lipids is endogenous and exogenous in 2 ways.”
Goutama, I. L., Hendsun, H., Firmansyah, Y., & Su, E. (2020) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20204512 · Cited by 5
Rocha, M. B., Ziolkowski, M. I., Bittencourt, R. A., Quintana, L. D., & Bender, E. A. (2021) · Saúde (Santa Maria) · doi:10.5902/2236583455296 · Cited by 1
Nurwati, I., Risya Cilmiaty, A. R., Hermawan, D., Saptiwi, B., Budiani, D. R., Subandono, J., Martini Mauri, M., Muthmainah, M., Sarsono, S., & Handayani, S. (2021) · Jurnal Riset Kesehatan · doi:10.31983/jrk.v10i2.7703 · Cited by 1
Hypolipidemic Effects and Mechanisms of Val-Phe-Val-Arg-Asn in C57BL/6J Mice and 3T3-L1 Cell ModelsPreprint
Wei, S., He, H., Ruge, C., & Hou, T. (2019) · Preprints.org · doi:10.20944/preprints201909.0309.v1
Tang, Y., Chen, C., Su, H., Tang, Z., Yue, J., Luo, X., & Liu, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1235925/v1 · Cited by 1
LipoGlo: A sensitive and specific reporter of atherogenic lipoproteinsPreprint
Thierer, J. H., Ekker, S. C., & Farber, S. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/522615
“50 Many of the genetic and environmental factors governing ABCL size and abundance remain 51 undiscovered or poorly characterized [9-11], and even fewer have been successfully targeted 52 pharmaceutically [12-14].”
BackgroundFarr, S. (2017) · TSpace (University of Toronto)
Hadj-Benali, Z., Diaf, M., & Khaled, M. B. (2019) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2019-0045
“A significant reduction in cardiovascular events has been observed in a large number of large-scale, randomized and clinical trials on LDL reducing therapies [7].”
BackgroundAtherogenic dyslipidemia typical for metabolic syndrome
Blaha, V., Víšek, J., & Lášticová, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.003
“Změny označujeme jako komplex aterogenní dyslipidemie (1).”
InfluentialDetermination of Small and Dense of Low-Density Lipoprotein and Coronary Heart Disease
李, 国. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.118514
Yurista, S., & Aditiawati, P. (2021) · 3BIO Journal of Biological Science Technology and Management · doi:10.5614/3bio.2021.3.2.3 · Cited by 2
High-density lipoprotein cholesterol — friend or enemy?
Murzakhanova, A. F., OSLOPOV, V. N., Sergienko, K. S., Khazova, E. V., & OSLOPOVA, J. V. (2022) · Kazan medical journal · doi:10.17816/kmj2022-79
Chen, C., Su, H., Tang, Z., Yue, J., Liu, C., Tang, Y., & Luo, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1235925/v2 · Cited by 1
Omoaghe, A. O., Oyesola, O., Ezike, T., Omizu, B., & Boone, K. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163819666220408100011 · Cited by 2
Damle, A. J., Thorat, S. T., Kasireddy, S. R., Yeleshwaram, V. R., & Mehta, P. J. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns1.5749
“Xiao et al coined the term atherogenic dyslipidemia to encompass these cluster of abnormalities: hypertriglyceridemia, low HDL cholesterol (HDL-C) levels, high small dense LDL (sdLDL) levels, elevated levels of remnant lipoproteins, and postprandial hyperlipidemia.[5] Persistently elevated triglycerides (TG) (non-fast…”
BackgroundEvaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.06.003 · Cited by 1
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Alsammarraie, H. J. M., Abdulwahed, A. M. H., Abdulrahman, M. A., Alkanaani, M. I. M., & Alelyan, U. A. A. (2022) · AIP conference proceedings · doi:10.1063/5.0121365
Murodov, O. R. T. A. S., Teshaev, O. R., & Mavlyanov, O. (2023) · Journal of Propulsion Technology · doi:10.52783/tjjpt.v44.i4.2114 · Cited by 2
“In the case of obesity, the release of many fatty acids from adipocytes induces their accumulation in the liver[46].”
BackgroundShahraz, J., Joukar, F., Yeganeh, S., Sheida, F., Maroufizadeh, S., Baghaei, M., Naghipour, M., & Mansour‐Ghanaei, F. (2023) · Research Square · doi:10.21203/rs.3.rs-3781497/v1
Elevated serum NLR and PLR are associated with a higher risk of atherosclerotic renal stenosisPreprint
Xu, G., Wu, Y., Tang, Y., Huang, X., Wu, J., Li, K., & Xu, G. (2024) · Research Square · doi:10.21203/rs.3.rs-3829803/v1
Ser, Ö. S., Sigirci, S., Keskin, K., Cetinkal, G., Kocas, B. B., Kilci, H., Dalgic, Y., Kalender, E., & Kilickesmez, K. (2024) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2024.40336
“[7,8] Several studies have shown that small-dense LDL-C (sdLDL-C) is more atherogenic than total LDL-C.”
BackgroundEVALUATION OF ELABELA LEVELS IN OBESE INDIVIDUALS
Yeniel, N., Caniklioğlu, A., Ozan, Z. T., Ercan, M., & Polat, M. F. (2024) · Bozok Tıp Dergisi · doi:10.16919/bozoktip.1438185 · Cited by 1
Role of fatty acid-binding proteins in obesity and obesity-mediated diseases
Duttaroy, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95700-7.00010-3
Unravelling the risk factors and treatment patterns of dyslipidemia in India (UNICORN study)
Mayabhate, M. M., & Sharma, A. D. (2024) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20244110
Avcı, D., Avcı, A., Ertaş, R., Özyurt, K., Ulaş, Y., Çetinkaya, A., & Mustafa, A. (2025) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_321_24
Metadata
- Authors
- Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F.
- Affiliations
- University of Toronto (CA)
- Western University (CA)
- Corresponding author
- Lewis, Gary F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-06-13
- Volume
- 65
- Issue
- 7
- Pages
- 1767-1778
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2472281584
- Cited by
- 212
- References
- 137
- Citations by year
- 2026: 6 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 25 · 2018: 13 · 2017: 12 · 2016: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430, MOP-43839)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- residual cardiovascular risk, hypertriglyceridemia, low HDL cholesterol, remnant lipoproteins, postprandial lipemia, triglyceride-rich lipoproteins, insulin resistance, type 2 diabetes, obesity, fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, drug repurposing, cardiovascular disease prevention
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.